LAEKNA-B Reports 2025 Revenue of Approximately 107 Million Yuan, R&D Expenses Up 16.17%

Stock News03-18 18:58

LAEKNA-B (02105) announced its 2025 financial results, achieving revenue of approximately 107 million yuan and a gross profit of 86.419 million yuan. Research and development expenses reached about 250 million yuan, representing a year-on-year increase of 16.17%. The net loss narrowed to approximately 229 million yuan, a decrease of 9.82% compared to the previous year.

The company stated that the 2025 revenue was derived from an out-licensing agreement with Qilu Pharmaceutical for LAE002 (afuresertib). The rise in R&D expenses was primarily due to increased costs associated with the ActRII product portfolio, which includes LAE102, LAE103, and LAE123, as well as higher equity-settled share-based payment expenses.

As of December 31, 2025, the company had initiated seven clinical trials for LAE102, LAE103, LAE002 (afuresertib), LAE001, and LAE005, targeting unmet medical needs in the areas of obesity and cancer.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1175483077?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-18 18:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1175483077","market":"sg","top_or_hot":-1,"title":"LAEKNA-B Reports 2025 Revenue of Approximately 107 Million Yuan, R&D Expenses Up 16.17%","media":"Stock News","content":"<p>LAEKNA-B (02105) announced its 2025 financial results, achieving revenue of approximately 107 million yuan and a gross profit of 86.419 million yuan. Research and development expenses reached about 250 million yuan, representing a year-on-year increase of 16.17%. The net loss narrowed to approximately 229 million yuan, a decrease of 9.82% compared to the previous year.</p>\n<p>The company stated that the 2025 revenue was derived from an out-licensing agreement with Qilu Pharmaceutical for LAE002 (afuresertib). The rise in R&D expenses was primarily due to increased costs associated with the ActRII product portfolio, which includes LAE102, LAE103, and LAE123, as well as higher equity-settled share-based payment expenses.</p>\n<p>As of December 31, 2025, the company had initiated seven clinical trials for LAE102, LAE103, LAE002 (afuresertib), LAE001, and LAE005, targeting unmet medical needs in the areas of obesity and cancer.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LAEKNA-B Reports 2025 Revenue of Approximately 107 Million Yuan, R&D Expenses Up 16.17%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLAEKNA-B Reports 2025 Revenue of Approximately 107 Million Yuan, R&D Expenses Up 16.17%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-18 18:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LAEKNA-B (02105) announced its 2025 financial results, achieving revenue of approximately 107 million yuan and a gross profit of 86.419 million yuan. Research and development expenses reached about 250 million yuan, representing a year-on-year increase of 16.17%. The net loss narrowed to approximately 229 million yuan, a decrease of 9.82% compared to the previous year.</p>\n<p>The company stated that the 2025 revenue was derived from an out-licensing agreement with Qilu Pharmaceutical for LAE002 (afuresertib). The rise in R&D expenses was primarily due to increased costs associated with the ActRII product portfolio, which includes LAE102, LAE103, and LAE123, as well as higher equity-settled share-based payment expenses.</p>\n<p>As of December 31, 2025, the company had initiated seven clinical trials for LAE102, LAE103, LAE002 (afuresertib), LAE001, and LAE005, targeting unmet medical needs in the areas of obesity and cancer.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1175483077","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1175483077","pubTimestamp":1773831501,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"LAEKNA-B (02105) announced its 2025 financial results, achieving revenue of approximately 107 million yuan and a gross profit of 86.419 million yuan. Research and development expenses reached about...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02105":"来凯医药-B"},"translate_title":"LAEKNA-B报告2025年营收约1.07亿元研发费用增长16.17%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02105":1},"content_text":"LAEKNA-B (02105) announced its 2025 financial results, achieving revenue of approximately 107 million yuan and a gross profit of 86.419 million yuan. Research and development expenses reached about 250 million yuan, representing a year-on-year increase of 16.17%. The net loss narrowed to approximately 229 million yuan, a decrease of 9.82% compared to the previous year.\nThe company stated that the 2025 revenue was derived from an out-licensing agreement with Qilu Pharmaceutical for LAE002 (afuresertib). The rise in R&D expenses was primarily due to increased costs associated with the ActRII product portfolio, which includes LAE102, LAE103, and LAE123, as well as higher equity-settled share-based payment expenses.\nAs of December 31, 2025, the company had initiated seven clinical trials for LAE102, LAE103, LAE002 (afuresertib), LAE001, and LAE005, targeting unmet medical needs in the areas of obesity and cancer.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1175483077","isCrawlerRequest":true}